ABSTRACT
InTRoduCTIon
Advances in cancer management have substantially improved the life expectancy in the past 2 decades [1] . Cancer therapy induced cardiotoxicity is responsible for considerable morbidity and mortality. Cardiotoxicity can cause interruption of oncologic treatment and reduction of therapeutic options. It can reduce the quality of life and survival [2] . Cancer treatment-related cardiotoxicity is the leading cause of treatment-associated mortality in survivors of pediatric and adolescent cancers, after recurrence and second or subsequent malignancies [3] . Cardiotoxicity is one of the most common post-treatment issues among five-to ten--year male survivors of adult cancer and second most common issue among female survivors of adult cancer [4] . More than onehalf of all patients exposed to anthracyclines show some degree of cardiac dysfunction 10 to 20 years after chemotherapy, and 5% of them develop overt HF [5] .
A wide range of chemotherapy agents have been associated with cardiotoxicity [6] . The most frequent cardiotoxicity is asymptomatic or symptomatic left ventricular dysfunction frequently occurring after administration of chemotherapy including anthracyclines [7] . Other cardiotoxic effects include hypertension [8] , thromboembolic disease [9] , pericardial disease [10] , arrhythmias [11] and myocardial ischemia [12] . Radiation therapy can also lead to coronary artery disease and fibrotic changes of the valves, pericardium and myocardium [13] . Anthracyclines are most commonly used chemotherapeutic agent in the treatment of many solid tumors and hematologic malignancies [14] and are prime example of chemotherapy-induced nonreversible cardiotoxicity (type I agents) [15] .
The commonest causes of heart failure in India are rheumatic heart disease, ischemic heart disease and hypertensive heart disease. There is no epidemiological data from India on chemotherapy-related cardiac dysfunction and data on their long term outcomes are limited.
oBjeCTIve
To study the clinical profile of patients diagnosed with anthracycline-related cardiomyopathy (ARC) and factors affecting their response to heart failure (HF) therapy.
MATeRIAl And MeThodS
This is an analysis of prospectively collected data of patients with ARC registered in the cardiooncology clinic at a tertiary cancer centre in Mumbai, India.
PATIenTS
Patients registered at the cardiooncology clinic in the period 2010-2015 were included. Patients who were found to have LV dysfunction due to other causes (e.g. coronary artery disease, septic cardiomyopathy) were excluded.
ARC was diagnosed by 2Decho as left ventricular ejection fraction (LVEF) < 50% in patients who had received anthracycline-based chemotherapy. ARC was graded as per NCI CTCAE (V-3.0) criteria.
All patients were given anti-heart failure treatment.
dATA ColleCTIon
Demographic details, co-morbidities (hypertension, ischemic heart disease, diabetes), cancer diagnosis and treatment details including dose of drugs, serial LVEF on 2Decho, date of diagno- 
dATA AnAlySIS
The primary endpoint of the study was response to anti-heart failure treatment. Patients were considered responders if LVEF increased by at least 10 absolute points and non-responders if LVEF increased fewer than 10 absolute points or deteriorated after starting anti-failure treatment. Patients were considered complete responders if LVEF increased to 50% post anti-heart failure treatment, partial responders if LVEF increased at least 10 absolute points but less than 50%. Follow up period was includ- Outcome of anthracycline-related cardiomyopathy -experience of a cardiooncology clinic at a tertiary referral cancer centre A. Alahari Dhir, A. Daddi, S.P. Sawant 
dISCuSSIon
Anthracyclines are well-known to cause dose-dependent cardiotoxicity [1] . A study by Van Hoff et al. found that with cumulative doxorubicin doses of less than 400 mg/m 2 body surface area, the congestive heart failure (CHF) incidence was 0.14% and it in- Outcome of anthracycline-related cardiomyopathy -experience of a cardiooncology clinic at a tertiary referral cancer centre A. Alahari Dhir, A. Daddi, S.P. Sawant In our study 59.1% patients were responders (partial or complete). The overall survival was better in responders in our study.
Cumulative dose of doxorubicin was the only factor that was sig- anthracyclines [28] . Enalapril and when possible carvedilol were started when left ventricular impairment was detected.
The authors found that patients treated 1-4 months after anthracycline administration were significantly more likely to respond to medical therapy with improved EF and none of the patients treated after 6 months of anthracycline administration had complete recovery of EF. In another study from the same center, 2625 patients receiving anthracycline chemotherapy underwent echocardiography every three months during anthracycline therapy and for one year after completion of anthracycline therapy, and every six months for four additional years [29] . ACE inhibition (e.g. enalapril) and β-blocker treatment was initiated immediately after an impaired LVEF was detected in 226 patients. Eleven percent of the patients totally recovered a normal LVEF and 71 percent of the patients improved their LVEF by more than 5 percent.
Developing and understanding optimal prevention, early detection and treatment strategies for cancer therapy induced cardiotoxicity is an important aspect of cancer patients care, and may have a significant impact on the overall prognosis and survival of cancer patients.
The primary limitation of the present study is its retrospective nature. Mixed cohort with different therapeutic regimens were included. Data on change/stoppage of chemotherapy after development of LV dysfunction and the oncologic outcome was not captured.
ConCluSIon
Most patients with anthracycline-related cardiomyopathy were asymptomatic. ARC occurred even at lower cumulative doses.
Most patients were detected to have LV dysfunction in the first
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Outcome of anthracycline-related cardiomyopathy -experience of a cardiooncology clinic at a tertiary referral cancer centre A. Alahari Dhir, A. Daddi, S.P. Sawant year after last dose of cardiotoxic chemotherapy and there was a higher frequency of non-response in patients who received
